BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33200367)

  • 1. Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease.
    Ambinder RF
    Recent Results Cancer Res; 2021; 217():197-207. PubMed ID: 33200367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease.
    Hsieh WS; Lemas MV; Ambinder RF
    Transpl Infect Dis; 1999 Sep; 1(3):204-12. PubMed ID: 11428990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
    Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of solid organ recipients shedding Epstein-Barr virus DNA pre-transplant: A prospective study.
    Verghese PS; Schmeling DO; Filtz EA; Grimm JM; Matas AJ; Balfour HH
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28915342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV
    Chaganti S; Barlev A; Caillard S; Choquet S; Cwynarski K; Friedetzky A; González-Barca E; Sadetsky N; Schneeberger S; Thirumalai D; Zinzani PL; Trappe RU
    Adv Ther; 2023 Mar; 40(3):1267-1281. PubMed ID: 36681739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
    Heldman MR; Edlefsen KL; Pepper G; Kapnadak SG; Rakita RM; Fisher CE; Limaye AP
    Transpl Infect Dis; 2022 Dec; 24(6):e13933. PubMed ID: 36000190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
    Sen A; Enriquez J; Rao M; Glass M; Balachandran Y; Syed S; Twist CJ; Weinberg K; Boyd SD; Bernstein D; Trickey AW; Gratzinger D; Tan B; Lapasaran MG; Robien MA; Brown M; Armstrong B; Desai D; Mazariegos G; Chin C; Fishbein TM; Venick RS; Tekin A; Zimmermann H; Trappe RU; Anagnostopoulos I; Esquivel CO; Martinez OM; Krams SM
    Front Immunol; 2022; 13():994552. PubMed ID: 36304469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lytic and latent EBV gene expression in transplant recipients with and without post-transplant lymphoproliferative disorder.
    Kroll J; Li S; Levi M; Weinberg A
    J Clin Virol; 2011 Nov; 52(3):231-5. PubMed ID: 21900040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
    Green M; Michaels MG; Webber SA; Rowe D; Reyes J
    Pediatr Transplant; 1999 Nov; 3(4):271-81. PubMed ID: 10562971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.